Your browser doesn't support javascript.
loading
Incidence of public health surveillance-reported Clostridioides difficile infections in thirteen countries worldwide: A narrative review.
Angulo, Frederick J; Furtado, Melissa; Gonzalez, Elisa; Zhang, Pingping; Kelly, Patrick H; Moïsi, Jennifer C.
Afiliación
  • Angulo FJ; Vaccines & Antivirals, Chief Medical Affairs Office, Pfizer Biopharma, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA. Electronic address: Frederick.J.Angulo@pfizer.com.
  • Furtado M; Medical Engagement and Impact, Chief Medical Affairs Office, Pfizer Biopharma, The Capital 1802/1901, G Block, Bandra-Kurla Complex, Mumbai 400051, Maharashtra, India.
  • Gonzalez E; Vaccines & Antivirals, Chief Medical Affairs Office, Pfizer Biopharma, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
  • Zhang P; Medical Affairs Evidence Generation Statistics, Pfizer Research and Development, Collegeville, Pennsylvania, USA.
  • Kelly PH; Vaccines & Antivirals, Chief Medical Affairs Office, Pfizer Biopharma, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
  • Moïsi JC; Vaccines & Antivirals, Chief Medical Affairs Office, Pfizer Biopharma, 23-25 Avenue du Docteur Lannelongue, 75014 Paris, France.
Anaerobe ; 88: 102878, 2024 Jun 21.
Article en En | MEDLINE | ID: mdl-38909713
ABSTRACT
Clostridioides difficile infection (CDI) is an important cause of morbidity and mortality worldwide. Data from public health surveillance systems are important for estimating country-level CDI burden. CDI surveillance can be population-based or hospital-based. Population-based surveillance results in overall estimates of CDI incidence (cases per 100,000 population-per-year), and hospital-based surveillance results in estimates of hospital-based CDI incidence (cases per 10,000 patient-days) or CDI admission rates (cases per 1,000 admissions). We sought to better understand temporal trends in CDI incidence reported in publicly available surveillance data worldwide and describe varying surveillance methods. We identified 13 countries in Europe, North America, and Oceania with publicly available population-based and/or hospital-based CDI surveillance data in online reports and/or dashboards. Additional countries in Europe, in particular, also conduct hospital-based CDI surveillance. Inconsistent CDI case definitions and surveillance approaches between countries limit the interpretability of multi-country comparisons. Nonetheless, publicly available CDI surveillance data enabled us to compare CDI incidence among countries with population-based and/or hospital-based surveillance systems and to describe trends in CDI incidence within countries over time. The highest CDI incidence is in the United States. While there have been recent declines in CDI incidence in all countries, the CDI burden remains high, and the need persists for CDI prevention strategies in communities and healthcare settings.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Anaerobe Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Anaerobe Año: 2024 Tipo del documento: Article